Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1325 Avenue Of Americas, 28Th Floor NEW YORK NY 10019 |
Tel: | N/A |
Website: | https://brainstorm-cell.com |
IR: | See website |
Key People | ||
Jacob A. Frenkel Independent Chairman of the Board | Chaim Lebovits President, Chief Executive Officer | Stacy R. Lindborg Co-Chief Executive Officer |
Alla Patlis Chief Financial Officer, Controller | Uri Yablonka Executive Vice President, Chief Business Officer, Secretary, Director | Ibrahim B. Dagher Executive Vice President, Chief Medical Officer |
Business Overview |
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology. |
Financial Overview |
For the fiscal year ended 31 December 2023, Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss decreased 29% to $17.2M. Lower net loss reflects Research and development - Balancing val decrease of 29% to $9.6M (expense), Stock-based Compensation in SGA decrease of 74% to $320K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.66 to -$0.40. |
Employees: | 29 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $33.85M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$21.17M as of Dec 31, 2023 |
Net annual income (TTM): | -$17.19M as of Dec 31, 2023 |
Free cash flow (TTM): | -$20.48M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 68,341,857 as of Mar 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |